BHA
VRTX icon

Beech Hill Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Beech Hill Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,325
Closed -$498K – 92
2017
Q4 		$498K Buy
+3,325
New +$492K 0.25% 61

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Beech Hill Advisors's VRTX Position: Q1 2018 in Review

Beech Hill Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2018, closing a stake of 3,325 shares — an estimated $498K sold.

Beech Hill Advisors first reported a position in VRTX in Q4 2017 and held it in 1 quarter. The position peaked at $498K in Q4 2017. 680 funds tracked by Wall St. Rank hold VRTX as of Q1 2018.

  • Beech Hill Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Beech Hill Advisors sold 3,325 Vertex Pharmaceuticals shares in Q1 2018, an estimated $498K.
  • Beech Hill Advisors first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Beech Hill Advisors's Vertex Pharmaceuticals position peaked at $498K in Q4 2017.
  • 680 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2018.

Based on Beech Hill Advisors's 13F filing for Q1 2018, filed 23 Apr 2018.